ADAR1 Buys InMed Shares to Fuel Merger‑Driven Migraine Drug Push
ADAR1’s strategic stake in InMed, merging with Mentari, fuels migraine‑prevention growth—capital, IP, and market access converge for a biopharma upside.
5 minutes to read
InMed Pharmaceuticals Inc
ADAR1’s $1.73 Share Buy Signals Confidence in InMed Pharma’s Cannabis‑Based Pipeline
ADAR1 Capital backs InMed Pharma’s CBD pipeline, with insider buying signaling confidence amid a merger; investors eye a potential rebound from today’s low.
3 minutes to read